Company Quick10K Filing
Cell Medx
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 44 $6
10-Q 2020-01-14 Quarter: 2019-11-30
10-Q 2019-10-15 Quarter: 2019-08-31
10-K 2019-09-06 Annual: 2019-05-31
10-Q 2019-04-22 Quarter: 2019-02-28
10-Q 2019-01-14 Quarter: 2018-11-30
10-Q 2018-10-15 Quarter: 2018-08-31
10-K 2018-09-13 Annual: 2018-05-31
10-Q 2018-04-16 Quarter: 2018-02-28
10-Q 2018-01-16 Quarter: 2017-11-30
10-Q 2017-10-17 Quarter: 2017-08-31
10-K 2017-08-29 Annual: 2017-05-31
10-Q 2017-04-14 Quarter: 2017-02-28
10-Q 2017-01-17 Quarter: 2016-11-30
10-Q 2016-10-17 Quarter: 2016-08-31
10-K 2016-09-13 Annual: 2016-05-31
10-Q 2016-04-14 Quarter: 2016-02-29
10-Q 2016-01-14 Quarter: 2015-11-30
10-Q 2015-10-15 Quarter: 2015-08-31
10-K 2015-09-03 Annual: 2015-05-31
10-Q 2015-04-14 Quarter: 2015-02-28
10-Q 2015-01-14 Quarter: 2014-11-30
10-Q 2014-10-09 Quarter: 2014-08-31
10-K 2014-08-26 Annual: 2014-05-31
10-Q 2014-04-18 Quarter: 2014-02-28
10-Q 2014-01-13 Quarter: 2013-11-30
10-Q 2013-10-03 Quarter: 2013-08-31
10-Q 2013-04-15 Quarter: 2013-02-28
10-Q 2013-01-16 Quarter: 2012-11-30
10-Q 2012-10-15 Quarter: 2012-08-31
10-K 2012-10-11 Annual: 2012-05-31
10-Q 2012-04-09 Quarter: 2012-02-29
10-Q 2012-03-02 Quarter: 2011-11-30
10-Q 2011-10-17 Quarter: 2011-08-31
10-K 2011-09-21 Annual: 2011-05-31
8-K 2019-06-24 Sale of Shares, Regulation FD, Exhibits
8-K 2019-03-21 Enter Agreement, Exhibits
8-K 2018-12-27 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-05-07 Officers, Exhibits
8-K 2018-03-23 Officers, Exhibits
CMXC 2019-11-30
Part I - Financial Information
Item 1. Financial Statements
Note 1 - Organization and Nature of Operations
Note 2 - Related Party Transactions
Note 3 - Inventory
Note 4 - Other Current Assets
Note 5 - Equipment
Note 6 - Unearned Revenue
Note 7 - Revenue
Note 8 - Notes and Advances Payable
Note 9 - Share Capital
Note 10 - Subsequent Event
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosure About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-10.53 cmxc_ex1053.htm
EX-10.54 cmxc_ex1054.htm
EX-10.55 cmxc_ex1055.htm
EX-10.56 cmxc_ex1056.htm
EX-10.57 cmxc_ex1057.htm
EX-10.58 cmxc_ex1058.htm
EX-10.59 cmxc_ex1059.htm
EX-31.1 cmxc_ex311.htm
EX-31.2 cmxc_ex312.htm
EX-32.1 cmxc_ex321.htm
EX-32.2 cmxc_ex322.htm

Cell Medx Earnings 2019-11-30

CMXC 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Comparables ($MM TTM)
Ticker M Cap Assets Liab Rev G Profit Net Inc EBITDA EV G Margin EV/EBITDA ROA
ETCK 6 0 8 0 0 -1 -1 6 77% -6.0 -340%
BABB 6 4 1 3 0 0 0 4 0% 9.4 11%
DIGP 6 1 1 2 0 -2 -1 6 27% -4.0 -124%
CMXC 6 0 2 0 0 -1 -1 6 -6.5 -472%
CCSB 6 52 45 0 0 -0 -0 3 78% -319.4 -0%
HCCC 6 4 2 5 2 -1 -0 5 38% -60.6 -15%
MOJO 6 0 0 2 1 0 0 6 50% 14.3 102%
FHRT 6 249 244 80 21 6 18 -3 26% -0.2 2%
NAUH 6 38 46 52 0 -25 -21 -3 0% 0.2 -66%
WSCO 6 0 0 0 0 0 0 6 0% 1,042.5 44%

10-Q 1 cmxc_10q.htm QUARTERLY REPORT 10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2019

 

or

 

[  ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

 

Commission File Number: 000-54500

 

Cell MedX Corp.

(Exact name of registrant as specified in its charter)

 

Nevada

 

38-3939625

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

123 W. Nye Ln, Suite 446

Carson City, NV

 

89706

(Address of principal executive offices)

 

(Zip code)

 

(844) 238-2692

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]  No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes [X]  No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  [  ]

 

Accelerated filer  [  ]

Non-accelerated filer  [  ]

 

Smaller Reporting Company [X]

 

 

Emerging Growth Company [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.)  Yes [  ]  No [X]

 

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 14, 2020 was 55,815,709.


 


 

CONTENTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


ii


PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

The accompanying unaudited consolidated interim financial statements of Cell MedX Corp. as at November 30, 2019, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

 

Operating results for the three and six months ended November 30, 2019, are not necessarily indicative of the results that can be expected for the year ending May 31, 2020.

 

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


1


CELL MEDX CORP.

CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)

(Unaudited)

 

 

 

November 30, 2019

 

May 31, 2019

 

 

 

 

ASSETS

 

 

 

 

 

 

 

Current assets

 

 

 

 Cash

$

274,991

 

$

57,172

 Inventory

 

77,789

 

 

73,201

 Other current assets

 

47,257

 

 

58,887

Total current assets

 

400,037

 

 

189,260

 

 

 

 

 

 

 Equipment

 

2,957

 

 

1,281

Total assets

$

402,994

 

$

190,541

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 Accounts payable

$

928,975

 

$

734,281

 Accrued liabilities

 

28,363

 

 

25,635

 Due to related parties

 

241,654

 

 

383,688

 Notes and advances payable

 

363,826

 

 

511,754

 Unearned revenue

 

307,850

 

 

307,742

Total liabilities

 

1,870,668

 

 

1,963,100

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

 

 

 Common stock, $0.001 par value, 300,000,000 shares authorized;

   55,815,709 and 44,282,749 shares issued and outstanding at

   November 30, 2019 and at May 31, 2019, respectively

 

55,816

 

 

44,283

 Additional paid-in capital

 

5,958,481

 

 

5,109,866

 Reserves

 

14,400

 

 

14,400

 Accumulated deficit

 

(7,505,597)

 

 

(6,956,822)

 Accumulated other comprehensive income

 

9,226

 

 

15,714

Total stockholders' deficit

 

(1,467,674)

 

 

(1,772,559)

Total liabilities and stockholders’ deficit

$

402,994

 

$

190,541

 

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.


F-2


 

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(Unaudited)

 

 

 

 

Three Months Ended

November 30,

 

Six Months Ended

November 30,

 

 

2019

2018

 

2019

2018

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 Sales

 

$

757

$

-

 

$

12,100

$

-

 Distribution rights

 

 

9,480

 

-

 

 

18,438

 

-

 Cost of goods sold

 

 

522

 

-

 

 

5,897

 

-

 Gross margin

 

 

9,715

 

-

 

 

24,641

 

-

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 Amortization

 

 

545

 

110

 

 

813

 

110

 Consulting fees

 

 

61,728

 

66,678

 

 

150,999

 

130,638

 Distribution expenses

 

 

19,173

 

-

 

 

35,620

 

-

 General and administrative expenses

 

 

132,080

 

24,448

 

 

218,642

 

52,077

 Research and development costs

 

 

95,894

 

33,633

 

 

156,607

 

183,367

 Total operating expenses

 

 

309,420

 

124,869

 

 

562,681

 

366,192

 

 

 

 

 

 

 

 

 

 

 

Other items

 

 

 

 

 

 

 

 

 

 

 Interest

 

 

(3,783)

 

(2,648)

 

 

(10,735)

 

(4,790)

Net loss

 

 

(303,488)

 

(127,517)

 

 

(548,775)

 

(370,982)

 

 

 

 

 

 

 

 

 

 

 

 Unrealized foreign exchange translation gain (loss)

 

 

453

 

6,477

 

 

(6,488)

 

7,346

Comprehensive loss

 

$

(303,035)

$

(121,040)

 

$

(555,263)

$

(363,636)

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share

 

 

 

 

 

 

 

 

 

 

 Basic and diluted

 

$

(0.01)

$

(0.00)

 

$

(0.01)

$

(0.01)

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding

 

 

 

 

 

 

 

 

 

 

 Basic and diluted

 

 

55,075,636

 

44,282,749

 

 

51,139,321

 

44,282,749

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.


F-3


 

 

CELL MEDX CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(Unaudited)

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

Additional

 

 

Other

 

 

Common Stock

Paid-in

 

Deficit

Comprehensive

 

 

Shares

Amount

Capital

Reserves

Accumulated

Income

Total

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

Balance - May 31, 2018

44,282,749

$

44,283

$

4,916,201

$

14,400

$

(6,050,841)

$

2,539

$

(1,073,418)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the six months

ended November 30, 2018

-

 

-

 

-

 

-

 

(370,982)

 

-

 

(370,982)

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

7,346

 

7,346

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - November 30, 2018

44,282,749

 

44,283

 

4,916,201

 

14,400

 

(6,421,823)

 

9,885

 

(1,437,054)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants issued for debt

-

 

-

 

193,665

 

-

 

-

 

-

 

193,665

Net loss for the six months

ended May 31, 2019

-

 

-

 

-

 

-

 

(534,999)

 

-

 

(534,999)

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

5,829

 

5,829

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - May 31, 2019

44,282,749

 

44,283

 

5,109,866

 

14,400

 

(6,956,822)

 

15,714

 

(1,772,559)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued for cash

4,050,000

 

4,050

 

481,950

 

-

 

-

 

-

 

486,000

Shares issued on exercise of warrants

7,482,960

 

7,483

 

366,665

 

-

 

-

 

-

 

374,148

Net loss for the six months

ended November 30, 2019

-

 

-

 

-

 

-

 

(548,775)

 

-

 

(548,775)

Translation to reporting currency

-

 

-

 

-

 

-

 

-

 

(6,488)

 

(6,488)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - November 30, 2019

55,815,709

$

55,816

$

5,958,481

$

14,400

$

(7,505,597)

$

9,226

$

(1,467,674)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.


F-4


 

 

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(Unaudited)

 

 

 

Six months ended

November 30,

 

2019

2018

 

 

 

Cash flows used in operating activities

 

 

 Net loss

$

(548,775)

$

(370,982)

Adjustments to reconcile net loss to net cash

 used in operating activities

 

 

 

 

 Accrued interest on notes payable

 

10,735

 

4,790

 Amortization

 

813

 

110

 Financing fees - non-cash

 

-

 

387

 Unrealized foreign exchange

 

(2,909)

 

(2,788)

Changes in operating assets and liabilities

 

 

 

 

 Inventory

 

(3,293)

 

(50,072)

 Other current assets

 

11,849

 

16,823

 Accounts payable

 

58,529

 

75,053

 Accrued liabilities

 

2,823

 

(13,107)

 Unearned revenue

 

(244)

 

250,000

 Due to related parties

 

(8,898)

 

26,352

Net cash flows used in operating activities

 

(479,370)

 

(63,434)

 

 

 

 

 

Cash flows used in investing activities

 

 

 

 

 Acquisition of equipment

 

(2,463)

 

(1,915)

Net cash used in investing activities

 

(2,463)

 

(1,915)

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 Advances payable

 

15,000

 

28,871

 Proceeds from notes payable

 

197,650

 

47,004

 Proceeds from subscription to shares

 

486,000

 

-

Net cash provided by financing activities

 

698,650

 

75,875

 

 

 

 

 

Effects of foreign currency exchange on cash

 

1,002

 

5,651

Increase in cash

 

217,819

 

16,177

 Cash, beginning

 

57,172

 

8,200

 Cash, ending

$

274,991

$

24,377

 

 

 

 

 

Non-cash financing transactions:

 

 

 

 

 Exercise of warrants for debt

$

374,148

$

-

 

 

 

 

The accompanying notes are an integral part of these interim consolidated financial statements.


F-5


 

CELL MEDX CORP.

NOTES TO THE UNAUDITED INTERIM

CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

NOVEMBER 30, 2019

 

 

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

 

Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development, and commercialization of therapeutic and non-therapeutic products that promote general wellness.

 

Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2019, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 6, 2019. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended November 30, 2019, are not necessarily indicative of the results that may be expected for the year ending May 31, 2020.

 

Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of November 30, 2019, the Company has not achieved profitable operations and has accumulated a deficit of $7,505,597. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

 

Recent accounting pronouncements

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2016-02,“Leases” (“ASU 2016-02”). ASU 2016-02 changes current U.S. GAAP for lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods. Early application is permitted. The Company adopted the ASU 2016-02 on June 1, 2019. As of the date of these financial statements, the Company has no leasing arrangements. However, the Company is evaluating a possible impact ASU 2016-02 may have on the Company’s decision to introduce leasing options for its eBalance® devices.

 

 


F-6


 

NOTE 2 - RELATED PARTY TRANSACTIONS

 

Amounts due to related parties, other than notes payable to related parties (Note 8) at November 30, 2019, and at May 31, 2019:

 

 

November 30, 2019

 

May 31, 2019

Due to the Chief Executive Officer (“CEO”)

$

97,200

 

$

75,600

Due to the Chief Financial Officer (“CFO”)

 

20,246

 

 

33,507

Due to the Vice President (“VP”), Technology and Operations

 

37,438

 

 

54,999

Due to the former Chief Medical Officer(1)

 

n/a

 

 

81,059

Due to the former CEO and director (1)

 

n/a

 

 

51,746

Due to the former VP, Corporate Strategy and major shareholder

 

86,770

 

 

86,777

Due to related parties

$

241,654

 

$

383,688

(1)The amounts due to former CEO and former Chief Medical Officer have been reclassified to accounts payable, as both persons were not related to the Company as at November 30, 2019. 

 

The amounts due to related parties are unsecured, due on demand and bear no interest.

 

During the six-month periods ended November 30, 2019 and 2018, the Company had the following transactions with related parties:

 

 

November 30, 2019

 

November 30, 2018

Management fees incurred to the CEO

$

21,600

 

$

21,600

Management fees incurred to the CFO

 

6,000

 

 

6,000

Consulting fees incurred to the VP, Technology and Operations

 

22,593

 

 

25,638

Interest accrued on loans from a major shareholder (Note 8)

 

7,095

 

 

4,294

Total transactions with related parties

$

57,288

 

$

57,532

 

NOTE 3 - INVENTORY

 

As at November 30, 2019, the inventory consisted of eBalance® devices and accessories held for sale valued at $46,832 (May 31, 2019 - $24,505) and work in progress, that included unfinished eBalance® devices and supplies required for manufacturing valued at $27,233 (May 31, 2019 - $48,696). In addition, the inventory included a total of $3,724 (May 31, 2019 - $Nil) associated with the eBalance® devices and accessories the Company provided to certain customers under 90- to 120-day trial periods, during which time the customers have an option to return the eBalance® devices at no charge and without obligation to purchase them.

 

The cost of eBalance® devices used for further research and development and for in-house observational trials is recognized as part of research and development expenses. During the six-month period ended November 30, 2019, the Company recognized $3,848 as the cost of eBalance® devices used in research and development. The cost of eBalance® devices used in marketing and advertising is recognized as part of general and administrative expenses. During the six-month period ended November 30, 2019, the Company recognized $5,358 as the cost of eBalance® devices used for marketing and advertising purposes.

 

NOTE 4 - OTHER CURRENT ASSETS

 

As at November 30, 2019, other current assets consisted of $2,528 in trade accounts receivable (May 31, 2019 - $Nil), $30,086 in prepaid expenses (May 31, 2019 - $50,331), and $14,643 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2019 - $8,556).

 

 


F-7


 

NOTE 5 - EQUIPMENT

 

Changes in the net book value of the equipment at November 30, 2019 and May 31, 2019 are as follows:

 

 

November 30, 2019

 

May 31, 2019

Book value, beginning of the period

$

1,281

 

$

-

Changes during the period

 

2,463

 

 

1,915

Amortization

 

(813)

 

 

(580)

Foreign exchange

 

26

 

 

(54)

Book value, end of the period

$

2,957

 

$

1,281

 

NOTE 6 - UNEARNED REVENUE

 

Changes to the unearned revenue as at November 30, 2019, and May 31, 2019:

 

 

November 30, 2019

 

May 31, 2019

Unearned revenue, beginning of the period

$

307,742

 

$

51,585

Deposits on distribution rights

 

25,000

 

 

250,000

Security deposits received from/(refunded to) customers

 

(2,269)

 

 

6,806

Security deposits recognized in sales

 

(4,537)

 

 

-

Non-refundable deposit on distribution rights

 

(18,438)

 

 

-

Foreign exchange

 

352

 

 

(649)

Unearned revenue, end of the period

$

307,850

 

$

307,742

 

During the six-month period ended November 30, 2019, the Company entered into a letter of intent for the wholesale distribution rights to all Mainland China, not including Hong Kong (the “LOI”). As part of the LOI, the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000. The LOI’s term is 240 days, in which for the first 120 days the Distributor is permitted to test the eBalance® devices (the “Testing Period”). During the Testing Period, the Company agreed not to enter into any agreements for the wholesale rights to Mainland China.

 

The Company amortizes the non-refundable deposit received from the Distributor on a straight-line basis over the full length of the LOI. As at November 30, 2019, $18,438 was recorded as revenue from distribution rights (Note 7).

 

NOTE 7 - REVENUE

 

During the six-month period ended November 30, 2019, the Company’s revenue consisted of sales of its eBalance® devices to end-users and sale of rights to the wholesale distribution of eBalance® devices.  Following are the details of revenue and associated costs:

 

 

Six months ended

November 30, 2019

Sales of eBalance® devices

$

12,100

Cost of eBalance® devices

 

(4,485)

Royalty payable

 

(1,412)

Distribution rights (Note 6)

 

18,438

Gross margin

$

24,641

 

 

 


F-8


 

NOTE 8 - NOTES AND ADVANCES PAYABLE

 

The tables below summarize the short-term loans and advances outstanding as at November 30, 2019, and May 31, 2019:

 

As at November 30, 2019

Principal

Outstanding

Interest Rate

per Annum

 

Accrued

Interest(5)

Total Book

Value

$

227,128

6%

Non-convertible(1)

$

5,247

$

232,375

 

6,873

6%

Related party(2)

 

107

 

6,980

 

35,606

6%

Related party(3)

 

552

 

36,158

 

88,313

0%

Advances(4)

 

--

 

88,313

$

357,920

 

 

$

5,906

$

363,826

 

As at May 31, 2019

Principal

Outstanding

Interest Rate

per Annum

 

Accrued

Interest(5)

Total Book

Value

$

29,065

6%

Non-convertible(1)

$

1,613

$

30,678

 

114,027

0%-12%

Related party(2)

 

12,533

 

126,560

 

275,000

6%

Related party (3)

 

6,468

 

281,468

 

73,048

0%

Advances(4)

 

--

 

73,048

$

491,140

 

 

$

20,614

$

511,754

 

(1) Loans Payable

During the six-month period ended November 30, 2019, in order to support its daily operations and to secure required working capital, the Company entered into several short-term convertible loan agreements with two lenders for a total of $197,650 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly.  Pursuant to the loan agreements, the lenders may convert any portion of principal and/or interest accrued thereon (the “Convertible Amount”) into restricted units of common stock in the capital of the Company on the terms and at a conversion price of the then-current private placement offering. The conversion rights were assessed to have $Nil value.

 

As at November 30, 2019, the Company owed a total of $232,375 (2019 - $30,678) under the 6% loan agreements, and recorded $3,620 in interest on these loans (2019 - $497).

 

(2) Related Party Loans Payable

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 2,482,960 warrants to acquire 2,482,960 shares of the Company granted in consideration for the funds Mr. Jeffs advanced to the Company during its fiscal 2019 and 2018 years.  To exercise the warrants, Mr. Jeffs chose to apply $124,148, the Company owed under the demand notes payable against the purchase price of the shares (Note 9). The exercise price was first applied to $15,051 (CAD$20,019) in interest accrued on the notes payable, with the remaining $109,097 (CAD$145,110) applied to the principal. The shares were issued on September 9, 2019. As at November 30, 2019, the Company owed Mr. Jeffs $6,980 under the remaining note payable (2019 - $126,560), which continues to accumulate interest at 6% per annum compounded monthly.

 

During the six-month period ended November 30, 2019, the Company recorded $2,422 in interest on the loans with Mr. Jeffs. (2019 - $4,294).

 

(3) Unsecured Line of Credit with Related Party

On August 28, 2019, Mr. Jeffs exercised 5,000,000 warrants to acquire 5,000,000 shares of the Company granted to Mr. Jeffs in consideration for an unsecured line of credit of up to $250,000 (the “Credit Line”) dated for reference December 27, 2018.  To exercise the warrants, Mr. Jeffs chose to apply $250,000, the Company owed under the Credit Line against the purchase price of the shares (Note 9). The exercise price was first applied to $10,606 in interest accrued on the balance due under the Credit Line, $25,000 was applied towards the Credit Line set-up fee, and the remaining $214,394 was applied to the principal. The shares were issued on September 9, 2019. As at November 30, 2019, the Company owed Mr. Jeffs $36,158 under the Credit Line (2019 - $281,468), which continues to accumulate interest at 6% per annum compounded monthly.


F-9


During the six-month period ended November 30, 2019, the Company recorded $4,673  in interest on principal outstanding under the Credit Line (2019 - $Nil).

 

(4) Advances Payable

During the six-month period ended November 30, 2019, the Company borrowed $15,000. The advances are non-interest bearing, unsecured, and payable on demand. As at November 30, 2019, a total of $88,313 (2019 - $73,048) was due and payable on account of the advances.

 

(5) Interest Expense

During the six-month period ended November 30, 2019, the Company recorded a total of $10,735 (2019 - $4,790) in interest expense associated with its liabilities under the notes and advances payable.

 

NOTE 9 - SHARE CAPITAL

 

On May 30, 2019, the Company announced a non-brokered private placement offering (the “2019 Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of up to $750,000. Each Unit sold under the 2019 Offering was to consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant. Each Warrant was to be exercisable into one share of the Company’s common stock at $0.20 per share.

 

On June 24, 2019, the Company closed the first tranche of its 2019 Offering by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019, the Company closed the second tranche of the 2019 Offering by issuing 100,000 Units for total gross proceeds of $12,000.

 

On September 9, 2019, the Company issued 7,482,960 common shares of the Company on exercise of 7,482,960 warrants the Company granted to Mr. Jeffs in consideration for the Credit Line and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements (Note 8). To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Credit Line and notes payable against the purchase price of the shares.

 

Options

 

The changes in the number of stock options outstanding during the six-month period ended November 30, 2019, and for the year ended May 31, 2019, are as follows:

 

 

Six months ended

November 30, 2019

 

Year ended

May 31, 2019

 

Number of

options

Weighted

average

exercise price

 

Number of

options

Weighted

average

exercise price

Options outstanding, beginning

7,050,000

$

0.24

 

9,450,000

$

0.35

Options cancelled

--

$

n/a

 

(2,400,000)

$

0.67

Options outstanding, ending

7,050,000

$

0.24

 

7,050,000

$

0.24

 

Details of options outstanding and exercisable as at November 30, 2019, are as follows:

 

Number of options outstanding and exercisable

Exercise price

Grant date

Expiry date

2,500,000

$0.05

November 25, 2014

August 26, 2020

2,500,000

$0.35

August 5, 2015

August 5, 2020

2,050,000

$0.35

August 24, 2017

August 23, 2022

7,050,000

$0.24

 

 

 

At November 30, 2019, the weighted average remaining contractual life of the stock options outstanding was 1.30 years.


F-10


 

Warrants

 

The changes in the number of warrants outstanding during the six-month period ended November 30, 2019, and for the year ended May 31, 2019, are as follows:

 

 

Six months ended

November 30, 2019

 

Year ended

May 31, 2019

Warrants outstanding, beginning

20,297,565

 

12,814,605

Warrants issued

4,050,000

 

7,482,960

Warrants exercised

(7,482,960)

 

--

Warrants outstanding, ending

16,864,605

 

20,297,565

 

Details of warrants outstanding as at November 30, 2019, are as follows:

 

Exercise price

Grant Date

Number of

warrants

exercisable

$0.60 during the period from March 3, 2019 to March 3, 2020

$0.75 during the period from March 3, 2020 to March 3, 2021

March 3, 2016

2,000,000

$1.25 during the period from October 12, 2019 to October 12, 2020

$1.50 during the period from October 12, 2020 to October 12, 2021

October 12, 2016

9,094,605

$1.50 during the period from October 12, 2019 to October 12, 2020

October 12, 2017

1,480,000

$1.00 during the period from February 7, 2019 to February 7, 2020

$1.50 during the period from February 7, 2020 to February 7, 2021

February 7, 2018

240,000

$0.20 expiring on June 24, 2021

June 24, 2019

3,950,000

$0.20 expiring on July 22, 2021

July 22, 2019

100,000

 

 

16,864,605

 

At November 30, 2019, the weighted average life and exercise price of the warrants was 1.61 years and $0.89, respectively.

 

NOTE 10 - SUBSEQUENT EVENT

 

Subsequent to November 30, 2019, the Company received $20,000 under convertible notes payable, which bear interest at 6% per annum compounded monthly. At the discretion of the lenders, the balances of the notes payable may be converted to units of the Company’s common stock at the price of the then-current private placement financing.

 

 

 

 

 

 

 

 

 

 

 

 

 


F-11


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.

 

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2019, filed with the United States Securities and Exchange Commission (the “SEC”) on September 6, 2019.

 

Overview

 

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.

 

On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance® Technology”).  With our acquisition of the eBalance® Technology, we have shifted our business direction to the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

 

On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada. As of the day of this Quarterly Report on Form 10-Q the Subsidiary is engaged in manufacturing, distribution, and further development of eBalance® Technology.

 

Recent Corporate Developments

 

The following corporate developments occurred during the quarter ended November 30, 2019, and up to the date of the filing of this report:

 

Exercise of Warrants

 

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised a total of 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the Line of Credit and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the $250,000 Credit Line and the notes payable against the purchase price of the shares. The shares were issued on September 9, 2019.

 

Convertible Loan Agreements

 

During the quarter ended November 30, 2019, in order to support our daily operations and to secure required working capital, we entered into several short-term convertible loan agreements with two lenders for a total of $197,650 in exchange for unsecured notes payable due on demand and accumulating 6% annual interest compounded monthly.  Subsequent to November 30, 2019, we advanced further $20,000 from the same lenders under substantially the same terms. Pursuant to the loan agreements, the lenders may convert  any portion of principal and/or interest accrued thereon into restricted units of our common stock on the terms and at a conversion price of the then-current private placement offering.


2


 

eBalance® Trademark

 

On October 17, 2019, we announced that European Union had approved our eBalance® trademark application, and issued certificate of registration number 017997155 registering the trademark eBalance® in our name. The eBalance® trademark was also registered in the U.K., bearing the registration number UK00003345540.  

 

The eBalance® trademark applications we filed with the Canadian Intellectual Property Office on November 14, 2017, and with the United States Patent and Trademark Office on December 11, 2017, continue to be under review.

 

The standard registered trademark symbol in Europe is ®. We are planning to use the designation eBalance® in our marketing efforts and for any print material until such time that Canadian and/or US trademark applications are approved.   

 

Update on eBalance Research and Development Progress

 

During the first quarter of the fiscal 2020, our Board of Directors approved commencement of a follow up study of our eBalance® device. The follow up study is being organized as a Family Practice (BC) - Observational Study (the “Study”). In order to commence the Study, which we are planning to conduct in a family practice medical clinic, we recruited Dr. Peter Eppinga, a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada, as the lead investigator in the Study.

 

The primary objective of the follow up Study is to further confirm safety of our eBalance® device with a secondary objective looking at baseline chronic care and complex care biometrics in a clinical family practice setting. Data from this Study will be shared with Health Canada and used to further support our application to the US FDA Premarket Notification 510(k) program to clear eBalance® for sale in the USA.

 

Results of Operations for the Three and Six Months ended November 30, 2019 and 2018

 

Our operating results for the three- and six-month periods ended November 30, 2019 and 2018, and the changes in the operating results between those periods are summarized in the table below.

 

 

Three Months Ended

 

Six Months Ended

 

 

November 30, 2019

November 30, 2018

Percentage

Increase/

(Decrease)

November 30, 2019

November 30, 2018

Percentage

Increase/

(Decrease)

Sales

$

757

$

-

n/a

$

12,100

$

-

n/a

Distribution rights

 

9,480

 

-

n/a

 

18,438

 

-

n/a

Cost of goods

 

(522)

 

-

n/a

 

(5,897)

 

-

n/a

Gross margin

 

9,715

 

-

n/a

 

24,641

 

-

n/a

Operating expenses

 

 

 

 

 

 

 

 

 

 

Amortization

 

545

 

110

395.5%

 

813

 

110

639.1%

Consulting fees

 

61,728

 

66,678

(7.4)%

 

150,999

 

130,638

15.6%

Distribution expenses

 

19,173

 

-

n/a

 

35,620

 

-

n/a

General and administrative expenses

 

132,080

 

24,448

440.2%

 

218,642

 

52,077

319.8%

Research and development costs

 

95,894

 

33,633

185.1%

 

156,607

 

183,367

(14.6)%

Total operating expenses

 

309,420

 

124,869

147.8%

 

562,681

 

366,192

53.7%

Interest

 

3,783

 

2,648

42.9%

 

10,735

 

4,790

124.1%

Net loss

$

303,488

$

127,517

138.0%

$

548,775

$

370,982

47.9%

 

Revenues

 

During the three-month period ended November 30, 2019, we recognized $757 (CAD$1,000) in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $522 and included $88 in royalties we accrued on the sales.

 

During the six-month period ended November 30, 2019, we recognized $12,100 (CAD$16,000) in revenue, which consisted of sales of our eBalance® wellness devices to end-users. The cost attributed to this revenue was $5,897 and included $3,713 in manufacturing costs of eBalance® devices, and $1,412 in royalties we accrued on the sales.


3


 

On June 6, 2019, we entered into a letter of intent for the wholesale distribution rights to all Mainland China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000, of which $18,438 we recorded as revenue from distribution rights for the six-month period ended November 30, 2019 ($9,480 for the three-month period ended November 30, 2019).

 

We did not generate any revenue during the three- and six-month periods ended November 30, 2018.

 

As of the date of this report on Form 10-Q, we continue research and further development of our eBalance® Technology and devices based on this technology, we are also working towards certifying our device with Health Canada as Class II medical device, and compiling required documentation for a 510(K) premarket submission with FDA, which allows to demonstrate that the eBalance® device is at least as safe and effective as a legally marketed device available on the market, which, if the submission is approved, will allow us to start our commercial activity in the USA. Until we receive Health Canada and FDA approvals, we will only be able to sell our devices as wellness devices in Canada, which will limit our potential revenue in a foreseeable future due to a smaller market share.

 

Operating Expenses

 

During the three-month period ended November 30, 2019, our operating expenses increased by 147.8% from $124,869 incurred during the three months ended November 30, 2018, to $309,420 we incurred during the three months ended November 30, 2019. The most significant expenses during this period included $83,181 in corporate communication fees (November 30, 2018 - $1,292), $95,894 we incurred in research and development fees (November 30, 2018 -  $33,633), $61,728 in consulting fees (November 30, 2018 - $66,678), $15,925 in accounting and audit fees (November 30, 2018 -  recovery of $2,230), and $19,173 we incurred in distribution expenses we paid or accrued to our sales representatives.

 

On a year-to-date basis, the most significant changes were as follows:

 

·During the six-month period ended November 30, 2019, our consulting fees increased by $20,361, from $130,638 we incurred during the three-month period ended November 30, 2018, to $150,999 we incurred during the six months ended November 30, 2019. Larger consulting fees during the three-month period ended November 30, 2019, were associated with $25,000 we paid for consultation on setting up our distribution channels in China. 

 

·Our research and development fees for the six-month period ended November 30, 2019, decreased by $26,760, from $183,367 we incurred during the six-month period ended November 30, 2018, to $156,607 we incurred during the six months ended November 30, 2019. The higher research and development fees during the six-month period ended November 30, 2018, resulted mainly from $140,460 (CAD$185,000) we incurred to Western Robotics Ltd., whom we engaged to assist us with enhancement and re-designing of our eBalance® Pro wellness devices. During the six months ended November 30, 2019, our improvements were mainly associated with integration of automated billing module and smaller updates and upgrades to the eBalance® device. 

 

·During the six-month period ended November 30, 2019, we incurred $35,620 in distribution expenses we paid or accrued to our sales representatives, who began working on distribution of our eBalance® devices in British Columbia, Canada (November 30, 2018 - $Nil). Based on our agreements with the sales representatives, we agreed to pay CAD$350 as commission for each eBalance® device they sell. In order to allow our sales representatives to establish their customer base, we agreed to a monthly fee of CAD$5,000 payable to each sales representative for an initial term of three months, which we have a right to extend on a month-to-month basis. 

 

·Our general and administrative fees for the six-month period ended November 30, 2019, increased by $166,565, or 319.8%, from $52,077 we incurred during the six-month period ended November 30, 2018, to $218,642 we incurred during the six months ended November 30, 2019. The largest factor that contributed to this change was associated with our expenditures on corporate communications per our services agreement with Think Ink Marketing, which resulted in $139,519 we recorded during the six-month period ended November 30, 2019, as compared to $1,778 we incurred during the six-month period ended November 30, 2018. Other factors that affected our general and administrative fees were associated with a $22,155 increase to our accounting and audit fees, which increased from $770 during the six-month period ended November 30, 2018, to $22,925 during the six-month period ended November 30, 2019, marketing  


4


and advertising fees, which increased by $5,785 as opposed to not having any expenses of this type during the comparative period ended November 30, 2018, and a $3,423 increase in office expenses from $2,809 we incurred during the six months ended November 30, 2018, to $6,232 we incurred during the six months ended November 30, 2019. These increases were offset by $1,531 decrease in travel and entertainment fees, which amounted to $1,987 during the six months ended November 30, 2019, and $1,797 decrease in foreign exchange, which resulted in $540 gain for the six-month period ended November 30, 2019, as opposed to $1,257 loss for the six months ended November 30, 2018.

 

Other Items

 

During the three-month period ended November 30, 2019, we accrued $3,783 (November 30, 2018 - $2,648) in interest associated with the outstanding notes payable. On a year-to-date basis, we accrued $10,738 in interest on the outstanding notes payable (November 30, 2018 - $4,790). Of this interest, during the six-month period ended November 30, 2019, we accrued $2,422 (November 30, 2018 - $4,294) on the notes payable we issued to Mr. Jeffs, our major shareholder, and $4,673 (November 30, 2018 - $Nil) we accrued on the Credit Line with Mr. Jeffs.

 

Liquidity and Capital Resources

 

Working Capital

 

 

As at

November 30, 2019

 

As at

May 31,

2019

 

Percentage

Change

Current assets

$

400,037

 

$

189,260

 

111.4%

Current liabilities

 

1,870,668

 

 

1,963,100

 

(4.7)%

Working capital deficit

$

(1,470,631)

 

$

(1,773,840)

 

(17.1)%

 

As of November 30, 2019, we had a cash balance of $274,991, a working capital deficit of $1,470,631 and cash flows used in operations of $479,370 for the period then ended. During the six-month period ended November 30, 2019, we funded our operations with $486,000 received from our private placement financing, $15,000 we borrowed under short-term non-interest bearing advances, and $197,650 we received under convertible loan agreements accumulating interest at 6% per annum, compounded monthly, and due on demand.

 

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2019. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under the outstanding notes and advances payable, or to service our other debt obligations.  If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

 

Cash Flows

 

 

Six months ended

November 30,

 

2019

 

2018

Cash flows used in operating activities

$

(479,370)

 

$

(63,434)

Cash flows used in investing activities

 

(2,463)

 

 

(1,915)

Cash flows provided by financing activities

 

698,650

 

 

75,875

Effects of foreign currency exchange on cash

 

1,002

 

 

5,651

Net increase in cash during the period

$

217,819

 

$

16,177


5


 

Net Cash Used in Operating Activities

 

Net cash used in operating activities during the six months ended November 30, 2019, was $479,370. This cash was primarily used to cover our cash operating expenses of $540,136, to increase our inventory by $3,293, and to decrease our unearned revenue and amounts due to related parties by $244 and $8,898, respectively. These uses of cash were offset by $11,849 decrease in other current assets, and by $58,529 and $2,823 increases in our accounts payable and accrued liabilities, respectively.

 

Net cash used in operating activities during the six months ended November 30, 2018, was $63,434. This cash was primarily used to cover our cash operating expenses of $368,483, to increase our inventory by $3,240, work in progress by $46,832, and to decrease our accrued liabilities by $13,107. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $75,053 and $26,352, respectively, by $16,823 increase to our current assets and by $250,000 increase in unearned revenue associated with a deposit we received under the LOI with Live Current Media, Inc.

 

Non-cash transactions

 

During the six-month period ended November 30, 2019, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

 

·$10,735 (2019 - $4,790) in interest we accrued on the outstanding notes payable. Of this interest, $2,422 (2019 - $4,294) was accrued on the notes payable we issued to Mr. Jeffs, and $4,673 (2019 - $Nil) was accrued on the $250,000 Credit Line provided to us by Mr. Jeffs; 

 

·$Nil (2019 - $387) in financing fees associated with notes payable we issued to Mr. Jeffs;  

 

·$2,909 (2019 - $2,788) gain in unrealized foreign exchange, which resulted from fluctuations of Canadian dollar denominated transactions; and 

 

·$813 (2019 - $110) in amortization of equipment we acquired for our manufacturing operations and for our office. 

 

Net Cash Provided by Financing Activities

 

During the six-month period ended November 30, 2019, we received $197,650 under convertible loan agreements, which are payable on demand and accumulate interest at 6% per annum. At discretion of the lenders, the full amount due under the loans can be converted into the units of our common stock at the then-current price of private placement financing. In addition, we received a total of $15,000 in non-interest-bearing advances which are payable on demand. In addition to the funds received as part of debt financing, we issued 4,050,000 units of our common stock for total proceeds of $486,000. We did not incur any share-issuance costs associated with the units issued as part of the private placement financing.

 

During the six months ended November 30, 2018, we borrowed a total of  $23,029 (CAD$30,000) from Mr. Jeffs, our major shareholder. Of this amount CAD$20,000 bore interest at 12% per annum, compounded monthly, was unsecured and payable on demand; and CAD$10,000 was advanced as a non-interest bearing short-term loan, which was payable within 14 days from the grant. In addition, we borrowed $23,975 (CAD$31,200) from an unrelated party. The loan bears interest at 6% per annum and is compounded monthly.  During the same period, we borrowed a total of $28,871 from unrelated parties under non-interest bearing advances which are payable on demand.

 

Net Cash Used in Investing Activities

 

During the six-month period ended November 30, 2019, we purchased three laptop computers for $2,463.

 

During the six months ended November 30, 2018, we spent $1,915 acquiring equipment for the manufacturing of our eBalance® devices.


6


 

Going Concern

 

The notes to our unaudited interim consolidated financial statements as at November 30, 2019, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage and as such, we were able to generate only minimal revenue from the operations. Our research and development as well as marketing plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing, or combination of both. In addition, we anticipate continuing to require upfront deposits from our potential distributors, once additional geographical distribution zones are determined.

 

We have accumulated a deficit of $7,505,597 since inception and increased sales will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our audited consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.

 

Off-Balance Sheet Arrangements

 

None.

 

Critical Accounting Policies

 

An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.

 

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

 

None.

 

Item 3. Quantitative and Qualitative Disclosure about Market Risk

 

None

 

Item 4. Controls and Procedures

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2019. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

 

During the quarter ended November 30, 2019, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.


7


 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

There is a high degree of risk associated with investing in our securities.  Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.

 

The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.

 

Risks Associated with our Company and our Industry

 

We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments.  Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.

 

The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.

 

We are subject to numerous governmental regulations which can increase our costs of developing our eBalance® Technology and products based on this technology.

 

Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.

 

Changes in the health care regulatory environment may adversely affect our business.

 

A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.


8


 

Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

 

Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.

 

Our research and development efforts may not result in the development of commercially successful products based on our eBalance® Technology, which may hinder our profitability and future growth.

 

Our eBalance® Technology is currently in the research and development stage as are our planned products incorporating this technology.  In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.

 

Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.

 

Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

 

New products and technological advances by our competitors may negatively affect our results of operations.

 

Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.

 

Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.

 

Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.

 

 


9


 

Inability to attract and maintain key personnel may cause our business to fail.

 

Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants.  If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.

 

To date we have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.

 

To date we have generated only minimal revenues. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing.  We have a very limited operating history and thus our progress as well as potential future success cannot be reasonably estimated.  Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance® Technology, of which there is no assurance. We continue to face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties.  Since inception, we have accumulated deficit of $7,505,597 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.

 

We need to acquire additional financing or our business will fail.

 

We must obtain additional capital or our business will fail. In order to continue development of our eBalance® Technology and to successfully carry out our planned clinical and observational trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on.  We currently have no arrangements for additional financing.  We may also have to borrow large sums of money that require substantial capital and interest payments.

 

Risks related to our stock

 

We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.

 

Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue.  However, there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.

 

There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.

 

Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.

 

Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.

 

Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations.  Liquidity may be low despite there being a market, making it difficult to get a return on the investment.  The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.


10


 

Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.

 

Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:

 

·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; 

·contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws; 

·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; 

·contains a toll-free telephone number for inquiries on disciplinary actions; 

·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and 

·contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation. 

 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

 

We have not paid nor anticipate paying cash dividends on our common stock.

 

We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history.  The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:

 

(a)we would not be able to pay our debts as they become due in the usual course of business; or 

(b)except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution. 

 

We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.


11


 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the $250,000 Credit Line and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Credit Line and notes payable against the purchase price of the shares. The shares were issued on September 9, 2019. The shares were issued pursuant to the provisions of Regulation S of the Act, as Mr. Jeffs is not resident of the United States and is otherwise not “U.S. Person” as that term is defined in Rule 902(k) of Regulation S of the Act.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

None.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit

 

 

Number

 

Description of Document

3.1

 

Articles of Incorporation (2)

3.2

 

Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(5)

3.3

 

Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(5)

3.4

 

Bylaws (1)

4.1

 

Specimen Stock Certificate (1)

10.4

 

Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)

10.5

 

First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7)

10.6

 

Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8)

10.7

 

Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)

10.8

 

Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9)

10.9

 

First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)

10.10

 

First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9)

10.11

 

Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10)

10.12

 

Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD.(10)

10.13

 

Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11)

 

 


12


 

Exhibit

 

 

Number

 

Description of Document

10.14

 

eBalance® Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi.(12)

10.15

 

Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(13)

10.16

 

Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp.

10.17

 

Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp.

10.18

 

Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp.(14)

10.19

 

Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp.(15)

10.20

 

Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)

10.21

 

Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs.(16)

10.22

 

Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.23

 

Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)

10.24

 

Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.25

 

Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)

10.26

 

Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)

10.27

 

Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs.(16)

10.28

 

Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)

10.29

 

Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp.(17)

10.30

 

Loan Agreement and Note Payable dated January 6, 2017, among Cell MedX Corp., and Richard N. Jeffs.(18)

10.31

 

Loan Agreement and Note Payable dated February 7, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)

10.32

 

Loan Agreement and Note Payable dated February 27, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)

10.33

 

Loan Agreement and Note Payable dated January 11, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)

10.34

 

Loan Agreement and Note Payable dated January 13, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)

10.35

 

Loan Agreement and Note Payable dated February 14, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)

10.36

 

Loan Agreement and Note Payable dated March 8, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19)

10.37

 

Loan Agreement and Note Payable dated April 18, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)

10.38

 

Loan Agreement and Note Payable dated May 5, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19)

10.39

 

Loan Agreement and Note Payable dated July 12, 2017, among Cell MedX Corp., and Richard N. Jeffs. (20)

10.40

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina(20)

10.41

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp.(20)

10.42

 

Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco (20)

10.43

 

Product Development Agreement for eBalance® dated October 16, 2017, among Cell MedX Corp. and Western Robotics Ltd.(21)

10.44

 

Management Consulting Agreement between Dr. Terrance Owen and Cell MedX Corp. dated effective as of December 1,  2017.(22)

10.45

 

Loan Agreement and Note Payable dated April 5, 2018, among Cell MedX Corp., and Richard N. Jeffs.


13


 

Exhibit

 

 

Number

 

Description of Document

10.46

 

Loan Agreement and Note Payable dated May 8, 2018, among Cell MedX Corp., and Richard N. Jeffs.

10.47

 

Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.

10.48

 

Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018.

10.49

 

Letter of Intent between the Company and Live Current Media, Inc. dated for reference September 10, 2018.

10.50

 

Loan Agreement and Note Payable dated September 13, 2018, among Cell MedX Corp., and Tradex Capital Corp. (23)

10.51

 

Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.(24)

10.52

 

Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. (25)

10.53

 

Loan Agreement and Note Payable dated September 4, 2019, among Cell MedX Corp. and Longview Investment Limited

10.54

 

Loan Agreement and Note Payable dated September 6, 2019, among Cell MedX Corp. and Rain Communications Corp.

10.55

 

Loan Agreement and Note Payable dated September 16, 2019, among Cell MedX Corp. and Longview Investment Limited

10.56

 

Loan Agreement and Note Payable dated September 19, 2019, among Cell MedX Corp. and Rain Communications Corp.

10.57

 

Loan Agreement and Note Payable dated September 20, 2019, among Cell MedX Corp. and Longview Investment Limited

10.58

 

Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Longview Investment Limited

10.59

 

Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Rain Communications Corp.

14.1

 

Code of Ethics(3)

31.1

 

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

 

The following materials from this Quarterly Report on Form 10-Q for the three- and six-month periods ended November 30, 2019 and 2018 formatted in XBRL (extensible Business Reporting Language):

 

 

(1) Unaudited Consolidated Balance Sheets at November 30, 2019 and as at May 31, 2019.

 

 

(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three- and six-month periods ended November 30, 2019 and 2018.

 

 

(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at November 30, 2019.

 

 

(4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the six-month periods ended November 30, 2019 and 2018.

 

(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010 

(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010 

(3)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014 

(4)Reserved 

(5)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014 

(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014 

(7)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014 

(8)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014 

(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014 

(10)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015 

(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015 

(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016 

(13)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015 

(14)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016 

(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016 

(16)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016 


14


 

 

(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016 

(18)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2017 

(19)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 29, 2017 

(20)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017 

(21)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 16, 2018 

(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on December 5, 2017. 

(23)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2019 

(24)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018 

(25)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


15


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Cell MedX Corp.

 

 

Date: January 14, 2020

By:

/s/ Frank McEnulty

 

 

Frank McEnulty

 

 

Chief Executive Officer and Director

 

 

(Principal Executive Officer)

 

 

 

Date: January 14, 2020

By:

/s/Yanika Silina

 

 

Yanika Silina

 

 

Chief Financial Officer and Director

 

 

(Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


16